Bookmarks
Evaluation of de novo diabetes or diabetes worsening in metastatic castration resistant prostate cancer patients treated with abiraterone acetate compared with enzalutamide in England.
Safe People
Astellas Pharma Europe Ltd
Commercial
Amit Kiran - Chief Investigator - Astellas Pharma Europe Ltd. - UKAmit Kiran - Corresponding Applicant - Astellas Pharma Europe Ltd. - UKKirsten Leyland - Collaborator - Astellas Pharma Europe Ltd. - UKMatthias Stoelzel - Collaborator - Astellas Pharma Europe Ltd. - UKRobert Snijder - Collaborator - Astellas Pharma Europe Ltd. - UK
Safe Projects
CPRD877
Prostate cancer is the one of the most common cancers in the UK for males. It encompasses a number of different clinical stages, with the most severe stage being when patients are not responding to hormonal therapy and the cancer has spread to other areas or organs. At this end stage, two of the key treatment options are abiraterone acetate (AA) and enzalutamide (Enza). One of the key distinguishing feature is that AA requires the co-administration of steroids, and Enza does not. Prolonged exposure to steroids can sometimes increase the risk of either developing or progressing conditions such as type 2 diabetes mellitus (T2DM). However little is known about this, in this vulnerable group of end stage prostate cancer patients.
Prostate cancer is the second most common cancer worldwide and the fifth most common cause of death. It is the most frequently diagnosed cancer among men in the United Kingdom (UK) with 48,487 new cases reported in 2017, accounting for 26% of all male cancer diagnoses. Prostate cancer encompasses a spectrum of clinical states that a patient progresses through over time.
09/02/2021
Safe Data
HES Admitted Patient Care
NCRAS Cancer Registration Data
NCRAS Systemic Anti-Cancer Treatment (SACT) data
ONS Death Registration Data
Safe Setting
Release